Ovarian Cancer Market to Register Sustainable Growth During the Forecast Period (2022-32) – DelveInsight | Clovis Oncology (Rubraca/rucaparib), ImmunoGen (Mirvetuximab soravtansine/IMGN853), Genentech

Ovarian Cancer Market to Register Sustainable Growth During the Forecast Period (2022-32) - DelveInsight | Clovis Oncology (Rubraca/rucaparib), ImmunoGen (Mirvetuximab soravtansine/IMGN853), Genentech
Delveinsight Business Research LLP
As per DelveInsight, the Ovarian Cancer market size shall grow in the coming years owing to the increased Research and Development (R&D) activities in the therapeutics segment and growth in the patient pool. Pharmaceutical companies are working toward developing potential therapies for ovarian cancer to fulfill the unmet medical needs of the currently used therapeutics.

Globally, about 100+ key pharma and biotech companies are working in the Ovarian Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

DelveInsight’s “Ovarian Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Ovarian Cancer Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Ovarian Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Ovarian Cancer Market

Ovarian Cancer: An Overview

Ovarian cancer is a disease that affects women and is a group of diseases that originates in the ovaries or in the related areas of the fallopian tubes and the peritoneum. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.

Platinum-based chemotherapy (usually in combination with surgery) is the mainstay of first-line drug treatment for ovarian cancer tumors. Optimal management of advanced ovarian cancer includes histopathological diagnosis, accurate surgical staging, debulking surgery, and platinum-based chemotherapy. The combination of carboplatin and paclitaxel is commonly recognized as the standard regimen because of tolerability and activity.

Despite advances in the field, most cases are diagnosed in the advanced stage, with a limited chance of being cured. Developing rational and effective screening and cancer prevention strategies for ovarian cancer, particularly high-grade serous cancer, requires a better understanding of the origin of this disease.

Ovarian Cancer Market Key Facts

  • In the United States, the incidence of ovarian cancer is 11.2 per 100,000 women per year,  based on 2013-2014 cases. (As per the National Cancer Institute, 2020)

  • About half of women diagnosed with ovarian cancer are 63 years or older. It is more common in white women than in African-American women. The rate at which women are diagnosed with ovarian cancer has been slowly falling over the past 20 years. (The American Cancer Society, 2020).

Ovarian Cancer Market 

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Ovarian Cancer market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Ovarian Cancer market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Ovarian Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Ovarian Cancer Epidemiology Segmentation

  • Total Incident Cases of Ovarian Cancer

  • Type-specific Incident Cases of Ovarian Cancer

  • Grade-specific Incident Cases of Ovarian Cancer

  • Diagnosed and Treatable Cases of Ovarian Cancer

Ovarian Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ovarian Cancer market or expected to get launched during the study period. The analysis covers Ovarian Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ovarian Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Key Developments in the Ovarian Cancer Therapeutics Market

On September 13, 2022, Clovis Oncology, Inc. (NASDAQ: CLVS) announced that it had submitted a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) and a Type II variation with the European Medicines Agency (EMA) for the approval of Rubraca® (rucaparib) as first-line maintenance treatment for women with advanced ovarian cancer.

On May 23, 2022, ImmunoGen announced that the US FDA has accepted and filed the Biologics License Application (BLA) for mirvetuximab soravtansine monotherapy in patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer who have been previously treated with 1 to 3 prior systemic treatments.

As per Delveinsight, the dynamics of the Ovarian Cancer market are anticipated to change in the coming years owing to the rise in healthcare spending worldwide and the ongoing clinical and commercial development activities in the therapeutics segment.

Learn How Ovarian Cancer Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/ovarian-cancer-market

Ovarian Cancer Therapeutics Analysis

To redress the existing issues, currently, there are many possible new treatment options emerging from recent clinical trials, based both on the modifications of standard approaches and on the addition of new biological drugs to the standard treatment.

There are approx. 100+ key companies which are developing therapies for Ovarian Cancer. Currently, Genentech has its ovarian Cancer drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Ovarian Cancer Market include:

  • Immunogen

  • Precigen

  • Roche

  • OncoQuest

  • Ellipses Pharma

  • Artios Pharma

  • Oncology Venture

  • ImmunoVaccine Technologies

  • Harpoon Therapeutics

And others.

Ovarian Cancer Therapies Covered in the report includes:

  • 2X-121 

  • ART0380

  • EP0057

  • HPN536

  • Oregovomab 

  • PRGN-3005 UltraCAR-T 

  • PX-Survivac

  • Mirvetuximab soravtansine

  •  Ipatasertib and Rucaparib combination 

And many more.

An improved understanding of Ovarian Cancer pathology and early diagnosis will lead to better treatment outcomes in the future. The expected launch of potential therapies in the market during the forecast period shall create a positive impact on the market size of ovarian cancer in the 7MM.

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More –


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Ovarian Cancer Competitive Intelligence Analysis

4. Ovarian Cancer Market Overview at a Glance

5. Ovarian Cancer Disease Background and Overview

6. Ovarian Cancer Patient Journey

7. Ovarian Cancer Epidemiology and Patient Population (In US, EU5, and Japan)

8. Ovarian Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Ovarian Cancer Unmet Needs

10. Key Endpoints of Ovarian Cancer Treatment

11. Ovarian Cancer Marketed Products

12. Ovarian Cancer Emerging Drugs and Latest Therapeutic Advances

13. Ovarian Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Ovarian Cancer Market Outlook (In US, EU5, and Japan)

16. Ovarian Cancer Access and Reimbursement Overview

17. KOL Views on the Ovarian Cancer Market

18. Ovarian Cancer Market Drivers

19. Ovarian Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:



About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Cutaneous Lupus Erythematosus Market

“Cutaneous Lupus Erythematosus Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Cutaneous Lupus Erythematosus Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/